QQ客服 官方微博 反馈留言

	Preclinical pharmacodynamics evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma.
	Yang Wei; Meng Lingwei; Chen Kai; Tian Chenyu; Peng Bing; Zhong Lei; Zhang Chunhui; Yang Xin; Zou Jun; Yang Shengyong
刊名	Cancer science
	2019
关键词	KRAS FOSL1 Src multi-kinase inhibitor pancreatic cancer
ISSN号	1349-7006
URL标识	查看原文
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/1818847
专题	四川大学
作者单位	Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, West China School of Pharmacy, Sichuan University, Chengdu, 610041, P. R. China. State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, P. R. China.
推荐引用方式 GB/T 7714	Yang Wei,Meng Lingwei,Chen Kai,et al. Preclinical pharmacodynamics evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma.[J]. Cancer science,2019.
APA	Yang Wei.,Meng Lingwei.,Chen Kai.,Tian Chenyu.,Peng Bing.,...&Li Linli.(2019).Preclinical pharmacodynamics evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma..Cancer science.
MLA	Yang Wei,et al."Preclinical pharmacodynamics evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma.".Cancer science (2019).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。